Fusion Antibodies form strategic collaboration with E2DG to provide end-to-end service for oncology drug discovery companies.
Posted on 11th November 2019 27th February 2020
The two companies will work together to deliver a seamless service offering for clients from discovery to manufacturing and PoC preclinical and phase I & II design and execution.
New technology for affinity maturation
Posted on 23rd August 2019 27th February 2020
Fusion Antibodies are working with a number of clients on pilot projects for their latest technology – RAMP™ – Rational Affinity Maturation Platform.
De-risking antibody development
Posted on 8th August 2019 24th October 2019
Why investing in pre-clinical activity is crucial to maximise the chance of success in clinical trials.
Fusion Antibodies are CIR approved
Posted on 7th August 2019 23rd August 2019
Fusion Antibodies has been granted approval to participate in the Crédit Impôt Recherche (CIR) scheme, meaning our French clients can enjoy a significant tax break by partnering with us for pre-clinical antibody research.
Fusion Antibodies celebrates Antibody Humanization Milestone
Posted on 7th June 2019 8th July 2019
Fusion Antibodies, a world leading CRO, has today announced that they have successfully completed their 150th Antibody Humanization project as part of their Antibody Engineering offering
Fusion Antibodies are attending Antibody Engineering & Therapeutics Asia
Posted on 15th February 2019 3rd July 2019
Fusion Antibodies are pleased to be attending Antibody Engineering & Therapeutics Asia on 26-28th February 2019 in Tokyo.